HR 9077 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Hormone Health Data and Research Act
To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause.
Summary
This bill directs the National Institutes of Health to review existing evidence on hormone level variability in women before they experience perimenopause symptoms, including baseline hormone patterns. The bill also requires the U.S. Preventive Services Task Force to review evidence on whether hormone testing before perimenopause symptoms occur helps diagnose or manage perimenopause. Both agencies must submit a joint report within 18 months to Congress summarizing their findings, identifying gaps in existing research, and providing recommendations for future research and clinical guidance.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
Actions (2)
- May 29, 2026 Referred to the House Committee on Energy and Commerce. · house
- May 29, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
May 29, 2026
Ms. Scholten introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Hormone Health Data and Research Act”.
SEC. 2. STUDIES ON HORMONE VARIABILITY AND HORMONE TESTING WITH RESPECT TO PERIMENOPAUSE.
(a) NIH Study.—The Director of the National Institutes of Health shall evaluate any evidence published on or prior to the date of enactment of this Act that relates to—
(1) the variability of hormone levels in a woman before such woman experiences symptoms of perimenopause; and
(2) any baseline pattern in such variability.
(b) U.S. Preventive Services Task Force Study.—The Secretary of Health and Human Services, acting through the United States Preventive Services Task Force, shall review any evidence published on or prior to the date of enactment of this Act related to the clinical utility of hormone testing, including whether baseline information obtained on the hormone levels of a woman before such woman experiences symptoms of perimenopause meaningfully informs the diagnosis or management of perimenopause for such woman.
(c) Report.—Not later than 18 months after enactment of this Act, NIH and USPSTF shall submit a report to the Committees on Appropriations of the House of Representatives and Senate, the Committee on Energy and Commerce of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions of the Senate summarizing findings, identifying evidence gaps, and providing recommendations for future research or clinical guidance. <all>
Comments